Compugen Ltd.

NasdaqCM:CGEN 株式レポート

時価総額：US$234.0m

Compugen 将来の成長

Future 基準チェック /06

Compugenの収益と利益はそれぞれ年間9%と34.6%減少すると予測されていますが、EPS は年間33.5% 減少すると予測されています。

主要情報

-34.6%

収益成長率

-33.48%

EPS成長率

Biotechs 収益成長29.0%
収益成長率-9.0%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日14 Aug 2026

今後の成長に関する最新情報

Recent updates

分析記事 • Aug 16

Analysts Have Just Cut Their Compugen Ltd. (NASDAQ:CGEN) Revenue Estimates By 14%

One thing we could say about the analysts on Compugen Ltd. ( NASDAQ:CGEN ) - they aren't optimistic, having just made a...
ナラティブ更新 • Jul 01

CGEN: Future Upside Will Depend On Advancing Immuno Oncology Pipeline Milestones

Compugen's analyst price targets have shifted sharply, with a leading firm cutting its target from $13 to $5, while other analysts remain bullish. This reflects updated views on the company's valuation and profit outlook.
ナラティブ更新 • Jun 17

CGEN: Bullish Views Persist As Immuno Oncology Pipeline Progress Supports Upside

Analysts have reduced their price target on Compugen stock to $5, down $8 from the prior $13 target, citing updated assumptions for discount rate, profit margin and future P/E, while maintaining a constructive fundamental view on the company. Analyst Commentary Recent research on Compugen stock reflects a mix of constructive views on the company and more cautious adjustments to valuation, giving you a clearer sense of how professionals are framing risk and reward.
ナラティブ更新 • Jun 02

CGEN: Bullish Initiation And Pipeline Execution Will Drive Future Upside

Analysts have reduced their fair value estimate for Compugen from $6.25 to $4.60, citing lower revenue growth expectations, a modestly higher discount rate, and updated long term profitability and P/E assumptions following recent price target cuts and a new bullish initiation on the stock. Analyst Commentary Recent Street research on Compugen reflects a split view, with some analysts maintaining a constructive stance while others are resetting expectations and price targets.
Seeking Alpha • May 19

Compugen: 'Buy' As Early Gastric Cancer Data Reinforces Rilvegostomig Program

Summary Compugen (CGEN) is maintained at a "Buy" rating, driven by advancing clinical programs and upcoming catalysts in oncology. Rilvegostomig, partnered with AstraZeneca, is being evaluated in 11 phase 3 studies, with strong phase 1b/2 data in HER2+ gastric cancer [70% cORR]. New data from DESTINY-Gastric03 will be presented at ASCO 2026, and interim analysis for COM701 in ovarian cancer is expected Q1 2027. CGEN has a cash runway into 2029, with $134.9M on hand and potential for $1B in milestone payments from AstraZeneca and Gilead partnerships. Read the full article on Seeking Alpha
ナラティブ更新 • May 03

CGEN: Future Upside Will Rely On Sustained Long Term Execution Confidence

Analysts have maintained their $13.00 price target on Compugen, citing recent bullish initiation and supportive research as reasons to keep their outlook. This remains the case despite slight adjustments to assumptions for the discount rate, revenue growth, profit margin, and future P/E.
ナラティブ更新 • Apr 07

CGEN: Future Upside Will Depend On Sustained Long Term Earnings Potential

Analysts maintained their target for Compugen at $13.00, citing updated assumptions that now reflect a slightly higher discount rate, a modestly weaker revenue growth outlook, a small reduction in expected profit margin, and a very large projected future P/E multiple. Valuation Changes Fair Value: Target remains at $13.00, with no change from the prior estimate.
ナラティブ更新 • Mar 22

CGEN: Unchanged US$13 Fair Value Will Rely On Long Term Earnings

Analysts kept their $13.00 price target for Compugen unchanged, with only small tweaks to underlying inputs such as discount rate, revenue growth assumptions, profit margin, and very large future P/E expectations supporting the decision to maintain the prior valuation view. Valuation Changes Fair Value: $13.00 fair value is unchanged, signaling no revision to the overall price target level.
ナラティブ更新 • Mar 06

CGEN: Royalty Monetization And Immuno Oncology Pipeline Will Drive Future Upside

Analysts have reiterated a $13.00 price target on Compugen, citing updated assumptions that include a slightly higher discount rate, a shift to an 11% revenue contraction, a lower profit margin near 12%, and a very large forward P/E estimate as the basis for their current stance. What's in the News Compugen agreed with AstraZeneca to monetize a portion of its future royalties from rilvegostomig, amending their 2018 exclusive license agreement to support Compugen's balance sheet and immuno oncology pipeline (Key Developments).
新しいナラティブ • Mar 03

Ovarian Trial Delays And Royalty Uncertainty Will Test This Long Runway Story

Catalysts About Compugen Compugen is a clinical stage immuno oncology company that uses a computational discovery engine to develop antibody based cancer therapies and out license assets to larger partners. What are the underlying business or industry changes driving this perspective?
ナラティブ更新 • Feb 20

CGEN: Royalty Sale And Oncology Pipeline Will Support Future Upside

Analysts have kept their price target for Compugen steady at $13.00, citing relatively unchanged fair value assumptions alongside small tweaks to the discount rate, very large projected revenue growth and expected profit margins, as well as an updated future P/E estimate. What's in the News Compugen and MedImmune Limited, part of the AstraZeneca Group, signed Amendment Number 4 to their March 30, 2018 license agreement covering rilvegostomig, updating the economic terms of Compugen's royalty interest (Key Developments).
ナラティブ更新 • Feb 06

CGEN: Royalty Monetization And Oncology Pipeline Will Drive Future Upside

Narrative Update on Compugen Analysts have kept their price target for Compugen steady at $13.00, citing only minor tweaks to assumptions around discount rate, very high projected revenue growth and profit margin that did not materially change their overall view. What's in the News Compugen agreed with AstraZeneca to monetize a portion of its future royalties from rilvegostomig, aiming to strengthen its balance sheet and support its immuno oncology pipeline (Key Developments).
ナラティブ更新 • Jan 23

CGEN: Future Upside Will Be Driven By Royalty Monetization Deal

Analysts have kept their fair value estimate for Compugen steady at $13.00, with only minor model tweaks to discount rates, revenue growth assumptions and future P/E, helping to refine rather than reset their overall price target view. What's in the News Compugen agreed with AstraZeneca to monetize a portion of its future royalties from the cancer drug candidate rilvegostomig, aiming to strengthen its balance sheet and support its immuno oncology pipeline (Key Developments).
ナラティブ更新 • Jan 09

CGEN: Future Upside Will Be Driven By Expanded Immuno Oncology Partnerships

Analysts have maintained their price target for Compugen at $13.00. They cite updated assumptions for discount rates, revenue growth, profit margins and a very large future P/E multiple as the main factors supporting this unchanged view.
ナラティブ更新 • Dec 14

CGEN: Future Revenue Trajectory Will Be Driven By Ongoing COM701 Program

Analysts have raised their price target on Compugen to 13.00 dollars from 13.00 dollars, citing sharply higher projected revenue growth, improved long term profit margins and a more favorable future earnings multiple, even after incorporating a slightly higher discount rate. What's in the News Pooled analysis of COM701 Phase 1 trials in 60 evaluable patients with platinum resistant ovarian cancer published as an abstract by the European Society of Medical Oncology, highlighting anti tumor activity and safety in heavily pre treated patients (ESMO abstract) Analysis details outcomes for patients deriving clinical benefit, including progression free survival data, and is based on data from prior COM701 studies in platinum resistant ovarian cancer (Company announcement) Additional year of follow up data on COM701 in platinum resistant ovarian cancer will be featured in an upcoming ESMO poster, expanding on the initial pooled findings (ESMO poster) Compugen estimates interim analysis results for the ongoing COM701 program to be available by year end 2026, guided by the anticipated enrollment rate (Company guidance) Valuation Changes Fair Value: Unchanged at 13.00 dollars per share, reflecting no revision to the base case price target.
分析記事 • Oct 07

There's No Escaping Compugen Ltd.'s (NASDAQ:CGEN) Muted Revenues Despite A 25% Share Price Rise

Compugen Ltd. ( NASDAQ:CGEN ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...
分析記事 • Oct 02

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
ナラティブ更新 • Aug 08

AI And Immunotherapy Advances Will Define Oncology's Future

Upward revisions to Compugen's revenue growth and net profit margin forecasts have driven a notable increase in its consensus analyst price target, which has risen from $5.50 to $6.25. What's in the News Compugen dosed the first patient in a global randomized sub-trial (MAIA-ovarian), evaluating its potential first-in-class anti-PVRIG antibody COM701 as maintenance therapy for relapsed platinum sensitive ovarian cancer.
分析記事 • May 25

Analysts Just Shaved Their Compugen Ltd. (NASDAQ:CGEN) Forecasts Dramatically

One thing we could say about the analysts on Compugen Ltd. ( NASDAQ:CGEN ) - they aren't optimistic, having just made a...
分析記事 • Apr 09

Is There An Opportunity With Compugen Ltd.'s (NASDAQ:CGEN) 33% Undervaluation?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Compugen fair value estimate is US$1.77 Current share price of...
分析記事 • Feb 26

Improved Revenues Required Before Compugen Ltd. (NASDAQ:CGEN) Shares Find Their Feet

You may think that with a price-to-sales (or "P/S") ratio of 2.9x Compugen Ltd. ( NASDAQ:CGEN ) is definitely a stock...
User avatar
新しいナラティブ • Jan 26

COM701 Trial Will Present Future Opportunities, But Competitive Risks Remain

Strategic advancements in drug development and partnerships could significantly bolster earnings and create opportunities in less competitive markets.
分析記事 • Aug 22

Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

You may think that with a price-to-sales (or "P/S") ratio of 4.1x Compugen Ltd. ( NASDAQ:CGEN ) is definitely a stock...
分析記事 • May 22

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

Compugen Ltd. ( NASDAQ:CGEN ) just released its first-quarter report and things are looking bullish. The results were...
分析記事 • May 01

Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

Compugen Ltd. ( NASDAQ:CGEN ) shareholders won't be pleased to see that the share price has had a very rough month...
分析記事 • Apr 05

Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Key Insights Compugen's estimated fair value is US$3.61 based on 2 Stage Free Cash Flow to Equity Compugen's US$2.32...
分析記事 • Mar 08

Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Despite an already strong run, Compugen Ltd. ( NASDAQ:CGEN ) shares have been powering on, with a gain of 26% in the...
分析記事 • Feb 17

Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, Compugen...
分析記事 • Oct 10

Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
分析記事 • Jun 22

Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

業績と収益の成長予測

NasdaqCM:CGEN - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/202818-27N/AN/A4
12/31/20278-27N/AN/A4
12/31/20269-26N/AN/A4
6/30/202674352828N/A
3/31/20267335N/AN/AN/A
12/31/202573353132N/A
9/30/20257-28N/AN/AN/A
6/30/202522-19-9-9N/A
3/31/202528-14N/AN/AN/A
12/31/202428-144950N/A
9/30/2024602N/AN/AN/A
6/30/202443-102222N/A
3/31/202436-17N/AN/AN/A
12/31/202333-19-36-36N/A
9/30/20238-32N/AN/AN/A
6/30/20238-33-32-32N/A
3/31/20238-33N/AN/AN/A
12/31/20228-34-35-34N/A
9/30/2022N/A-39N/AN/AN/A
6/30/20226-34-30-30N/A
3/31/20226-34N/AN/AN/A
12/31/20216-34-23-23N/A
9/30/20218-34N/AN/AN/A
6/30/20212-36-31-30N/A
3/31/20212-32N/AN/AN/A
12/31/20202-30-28-28N/A
9/30/2020N/A-28N/AN/AN/A
6/30/2020N/A-26-23-23N/A
3/31/2020N/A-26N/AN/AN/A
12/31/2019N/A-27N/A-28N/A
9/30/2019N/A-30N/AN/AN/A
6/30/20198-27N/A-22N/A
3/31/20198-31N/AN/AN/A
12/31/201818-23N/A-13N/A
9/30/201818-23N/AN/AN/A
6/30/201810-29N/A-23N/A
3/31/201810-28N/AN/AN/A
12/31/2017N/A-37N/A-31N/A
9/30/20170-36N/AN/AN/A
6/30/20170-34N/A-27N/A
3/31/20171-32N/AN/AN/A
12/31/20161-32N/A-20N/A
9/30/20169-23N/AN/AN/A
6/30/20169-22N/A-20N/A
3/31/20169-23N/AN/AN/A
12/31/20159-20N/A-26N/A
9/30/20158-21N/AN/AN/A

アナリストによる今後の成長予測

収入対貯蓄率: CGENの収益は今後 3 年間で減少すると予測されています (年間-34.6% )。

収益対市場: CGENの収益は今後 3 年間で減少すると予測されています (年間-34.6% )。

高成長収益: CGENの収益は今後 3 年間で減少すると予測されています。

収益対市場: CGENの収益は今後 3 年間で減少すると予想されています (年間-9% )。

高い収益成長: CGENの収益は今後 3 年間で減少すると予測されています (年間-9% )。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CGENの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/09/14 20:02
終値2026/09/11 00:00
収益2026/06/30
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Compugen Ltd. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10

アナリスト機関
Ling WangChardan Capital Markets, LLC
Michael KingCitizens JMP Securities, LLC
Swayampakula RamakanthH.C. Wainwright & Co.